Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Health adults of both genders~* Age ≥ 18 ≤ 50 years~* Able to understand every required study procedure~* Female volunteers should agree to take an acceptable contraceptive method Menopause is characterized by absence of menstrual flux for two consective years~* Normal values for pre-stablished laboratory assays~* Accpetance to participate and sign the consent form~Exclusion Criteria:~* Any chronic condition~* Be on immunossupressive or stimulant therapy~* Have egg alergy~* Have past history of alergy to sazonal influenza vaccine~* Have received another inactivated vaccine within the prior 2 weeks or a live vaccine in the past four weeks to his/her participation in the study~* Acute infectious disease during seven days prior vaccination~* Female on breasthfeeding~* Confirmed prior infection by pandemic influenza A~* Participation in another clinical trial in the last 6 months~* Any other condition identified by the principal investigator which is considered not safe for enrollment of the volunteer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- pandemic vaccine 1 (Type: EXPERIMENTAL): 7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
- pandemic vaccine 2 (Type: EXPERIMENTAL): 3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
- pandemic vaccine 5 (Type: EXPERIMENTAL): 7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
- pandemic vaccine 6 (Type: EXPERIMENTAL): 3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
- pandemic vaccine 9 (Type: EXPERIMENTAL): 7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
- pandemic vaccine 10 (Type: EXPERIMENTAL): 3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
- pandemic vaccine 11 (Type: EXPERIMENTAL): 7,5µg of A/H1N1 with Al(OH)3
- pandemic vaccine 12 (Type: EXPERIMENTAL): 3,75µg of A/H1N1 with Al(OH)3
- pandemic vaccine 13 (Type: EXPERIMENTAL): 15µg of A/H1N1 with no adjuvant
- placebo group 14 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).